#JPM18 Big Cap Biotech Recap


09-Jan-2018 20:51 PM



These are big cap biotech recap news at #JPM18. The stock price, as of Jan 09, 2018 closed.

  • Allergan Plc (AGN- Stock get updated from CEO, Saunders. call Botox a '$2.8 billion fortress', company's see FY18 revenue $15B-$15.3B vs $15.61B esttimate. Stock up +2.98% to $175.65.
  • Alnylam Pharmaceuticals Inc (ALNY)- restructuring with SNY. ALNY will get TTR and SNY take hemophilia. Stock up 1.21% to $130.74
  • Celgene Corp (CELG)- Nears deal to buy Impact Biomedinces for as much as $7B.  See Q4 revenue $3.48B vs $3.46B est. Stock up +1.26% to $105.49
  • Gilead Science Inc (GILD)- stock up +4.97% with CEO, John Miligan went on CNBC interviewed.  HIV is current growth.Stock up +4.97% to $78.10
  • Illuminia Inc (ILMN)- Thermo Fisher announce commerical agreement for Ion AmpliSeq. Report preliminary Q4 revenue $775M vs $736.6M. Stock up +6.93% to $242.80
  • Incyte Corp (INCY)- Social media speculating #NKTR drug is better. Stock down -4.48% to $96.29
  • Johnson & Johnson (JNJ)- CEO interviewed on CNBC says competition is good for the industry. Declined to comment in talk with Amazon drug distribution. Stock up +1.59% to $144.14
  • Vertex Pharmaceuticals Inc (VRTX)- global CF revenue view to $2.1B-$2.15B vs $1.79B-$2.01B. Stock down -0.56% to $156.01

Stay tuned, we'll update on these big cap biotech if there are any news release this week.

Contact us:

Twitter: @BiotechMoney18



Add Your Comment

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.